Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Youcheng Shen"'
Autor:
Weiyu Han, Weidong Xiong, Weixing Sun, Weiwei Liu, Yu Zhang, Chaofu Li, Ning Gu, Youcheng Shen, Zhimei Qiu, Chaozhong Li, Yongchao Zhao, Ranzun Zhao
Publikováno v:
Cell Transplantation, Vol 33 (2024)
The therapeutic efficacy of bone marrow mesenchymal stem cells (BMSCs) in myocardial infarction (MI) is hindered by poor cell survival. This study explored the role of N6-methyladenosine (m6A) regulation, specifically YTHDC1, in improving BMSC transp
Externí odkaz:
https://doaj.org/article/c0d01e3cb8504515ab6bd87fb82e0bb5
Autor:
Jin Sheng, Shuangya Yang, Ning Gu, Chancui Deng, Youcheng Shen, Qianhang Xia, Yongchao Zhao, Xi Wang, Yi Deng, Ranzun Zhao, Bei Shi
Publikováno v:
Heliyon, Vol 10, Iss 16, Pp e36486- (2024)
Background: In-stent neoatherosclerosis (ISNA) is identified as the primary cause of in-stent restenosis (ISR). The systemic immune inflammation index (SII), shows promise for predicting post-percutaneous coronary intervention (PCI) adverse cardiovas
Externí odkaz:
https://doaj.org/article/c4ed372ea1ee4edf86e8ea2b4ae2d75a
Autor:
Chancui Deng, Zhijiang Liu, Wei Zhang, Yi Deng, Hanlin Liu, Zhixun Bai, Jidong Rong, Wenwen Deng, Ning Gu, Youcheng Shen, Xingwei Hu, Yongchao Zhao, Ranzun Zhao, Bei Shi
Publikováno v:
Reviews in Cardiovascular Medicine, Vol 24, Iss 12, p 341 (2023)
Background: Neoatherosclerosis (NA) is associated with stent failure. However, systematic studies on the manifestations of NA and neovascularization (NV) at different stages after drug-eluting stent (DES) implantation are lacking. Moreover, the relat
Externí odkaz:
https://doaj.org/article/d8bd5373615f4033b4640939af2ad262
Autor:
Yongchao Zhao, Aichao Xia, Chaofu Li, Xianping Long, Zhixun Bai, Zhimei Qiu, Weidong Xiong, Ning Gu, Youcheng Shen, Ranzun Zhao, Bei Shi
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
N6-methylatidine (m6A) is involved in post-transcriptional metabolism and a variety of pathological processes. However, little is known about the role of m6A in vascular proliferative diseases, particularly in vascular smooth muscle cells (VSMCs) phe
Externí odkaz:
https://doaj.org/article/fe1b17a863b840bebe66adf7c9db2b30